Korean Medication Algorithm for Depressive Disorder: Comparisons with Other Treatment Guidelines

被引:17
|
作者
Wang, Hee Ryung [1 ]
Bahk, Won-Myong [1 ]
Seo, Jeang Seok [2 ]
Woo, Young Sup [1 ]
Park, Young -Min [3 ]
Jeong, Jong-Hyun [4 ]
Kim, Won [5 ,6 ]
Shim, Se-Hoon [7 ]
Lee, Jung Goo [8 ,9 ,10 ]
Jon, Duk-In [11 ]
Min, Kyung Joon [12 ]
机构
[1] Catholic Univ Korea, Dept Psychiat, Coll Med, Seoul, South Korea
[2] Konkuk Univ, Dept Psychiat, Sch Med, Chungju, South Korea
[3] Inje Univ, Coll Med, Dept Psychiat, Ilsan Paik Hosp, Goyang, South Korea
[4] Catholic Univ Korea, St Vincents Hosp, Dept Psychiat, Coll Med, Suwon, South Korea
[5] Inje Univ, Sch Med, Dept Psychiat, Seoul Paik Hosp, Seoul, South Korea
[6] Inje Univ, Stress Res Inst, Seoul, South Korea
[7] Soonchunhyang Univ, Dept Psychiat, Coll Med, Cheonan Hosp, Cheonan, South Korea
[8] Inje Univ, Dept Psychiat, Coll Med, Haeundae Paik Hosp, Busan, South Korea
[9] Inje Univ, Palk Inst Clin Res, Busan, South Korea
[10] Inje Univ, Dept Hlth Sci & Technol, Grad Sch, Busan, South Korea
[11] Hallym Univ, Sacred Heart Hosp, Dept Psychiat, Coll Med, Anyang, South Korea
[12] Chung Ang Univ, Dept Psychiat, Coll Med, Seoul, South Korea
关键词
Depressive disorder; Expert consensus; Guideline; KMAP DD 2017; Therapy; PSYCHIATRY WFSBP GUIDELINES; 2016 CLINICAL GUIDELINES; BIOLOGICAL TREATMENT; CANADIAN NETWORK; WORLD FEDERATION; MOOD; MANAGEMENT; SOCIETIES; ADULTS; LEVOMILNACIPRAN;
D O I
10.9758/cpn.2017.15.3.199
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
In this review, we compared recommendations from the Korean Medication Algorithm Project for Depressive Disorder 2017 (KMAP DD 2017) to other global treatment guidelines for depression. Six global treatment guidelines were reviewed; among the six, 4 were evidence based guidelines, 1 was an expert consensus based guideline, and 1 was an amalgamation of both evidence and expert consensus based recommendations. The recommendations in the KMAP DD 2017 were generally similar to those in other global treatment guidelines, although there were some differences between the guidelines. The KMAP DD 2017 appeared to reflect current changes in the psychopharmacology of depression quite well, like other recently published evidence based guidelines. As an expert consensus based guideline, the KMAP DD 2017 had some limitations. However, considering there are situations in which clinical evidence cannot be drawn from planned clinical trials, the KMAP DD 2017 may be,helpful for Korean psychiatrists making decisions in the clinical settings by complementing previously published evidence based guidelines.
引用
收藏
页码:199 / 209
页数:11
相关论文
共 50 条
  • [41] The influence of patients' preference/attitude towards psychotherapy and antidepressant medication on the treatment of major depressive disorder
    Moradveisi, Latif
    Huibers, Marcus
    Renner, Fritz
    Arntz, Arnoud
    JOURNAL OF BEHAVIOR THERAPY AND EXPERIMENTAL PSYCHIATRY, 2014, 45 (01) : 170 - 177
  • [42] Early intervention for bipolar disorder - Do current treatment guidelines provide recommendations for the early stages of the disorder?
    Fang, Chia Ming
    Cotton, Sue
    Filia, Kate
    Phelan, Mark
    Conus, Philippe
    Jauhar, Sameer
    Marwaha, Steven
    McGorry, Patrick D.
    Davey, Christopher
    Berk, Michael
    Ratheesh, Aswin
    JOURNAL OF AFFECTIVE DISORDERS, 2019, 257 : 669 - 677
  • [43] Effect of early medication adherence on behavioral treatment utilization and smoking cessation among individuals with current or past major depressive disorder
    Hitsman, Brian
    Papandonatos, George D.
    Fox, Erica N.
    Bauer, Anna-Marika
    Gollan, Jacqueline K.
    Huffman, Mark D.
    Mohr, David C.
    Leone, Frank T.
    Khan, Sadiya S.
    Achenbach, Chad J.
    Wileyto, E. Paul
    Schnoll, Robert A.
    ADDICTIVE BEHAVIORS, 2024, 151
  • [44] Pharmacological Treatment of Cognitive Symptoms in Major Depressive Disorder
    Pan, Zihang
    Grovu, Radu C.
    Cha, Danielle S.
    Carmona, Nicole E.
    Subramaniapillai, Mehala
    Shekotikhina, Margarita
    Rong, Carola
    Lee, Yena
    McIntyre, Roger S.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2017, 16 (08) : 891 - 899
  • [45] Psychosocial aspects of resistance in complex treatment of depressive disorder
    Sedlackova, Zuzana
    Prasko, Jan
    Latalova, Klara
    Kamaradova, Dana
    Ociskova, Marie
    Grambal, Ales
    Sigmundova, Zuzana
    Kasalova, Petra
    Cakirpaloglu, Snezana
    NEUROENDOCRINOLOGY LETTERS, 2015, 36 (04) : 354 - 362
  • [46] How does borderline personality disorder affect management and treatment response of patients with major depressive disorder? A comprehensive review
    Ceresa, Alessandro
    Esposito, Cecilia Maria
    Buoli, Massimiliano
    JOURNAL OF AFFECTIVE DISORDERS, 2021, 281 : 581 - 589
  • [47] Temporomandibular disorder treatment algorithm for otolaryngologists
    Lee, Esther
    Crowder, Hannah R.
    Tummala, Neelima
    Goodman, Joseph F.
    Abbott, Jeremy
    Zapanta, Philip E.
    AMERICAN JOURNAL OF OTOLARYNGOLOGY, 2021, 42 (06)
  • [48] Methodological differences between pharmacological treatment guidelines for bipolar disorder: what to do for the clinicians?
    Samalin, Ludovic
    Guillaume, Sebastien
    Courtet, Philippe
    Abbar, Mocrane
    Lancrenon, Sylvie
    Llorca, Pierre-Michel
    COMPREHENSIVE PSYCHIATRY, 2013, 54 (04) : 309 - 320
  • [49] Non-pharmacological treatment-related changes of molecular biomarkers in major depressive disorder: A systematic review and meta-analysis
    Irwin, Courtney L.
    Coelho, Patricia S.
    Kluwe-Schiavon, Bruno
    Silva-Fernandes, Anabela
    Goncalves, Oscar F.
    Leite, Jorge
    Carvalho, Sandra
    INTERNATIONAL JOURNAL OF CLINICAL AND HEALTH PSYCHOLOGY, 2023, 23 (03)
  • [50] Global perspectives on bipolar disorder treatment: in-depth comparative analysis of international guidelines for medication selection
    Park, Ji Hyun
    Fernando, Kaveesha
    Park, Youngja Hwang
    Park, Esther O.
    BJPSYCH OPEN, 2024, 10 (03):